|
ZBTB25 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62458935193399E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.63458135915562E-12 |
| Normal-vs-Stage2 |
5.5370999996196E-07 |
| Normal-vs-Stage3 |
3.10862446895044E-14 |
| Normal-vs-Stage4 |
4.46975789714088E-13 |
| Stage1-vs-Stage2 |
2.392400E-01 |
| Stage1-vs-Stage3 |
4.677800E-01 |
| Stage1-vs-Stage4 |
2.161800E-01 |
| Stage2-vs-Stage3 |
1.223000E-01 |
| Stage2-vs-Stage4 |
7.340300E-02 |
| Stage3-vs-Stage4 |
6.519800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.97242222554905E-12 |
| Normal-vs-AfricanAmerican |
1.577720E-04 |
| Normal-vs-Asian |
6.55142606831305E-13 |
| Caucasian-vs-AfricanAmerican |
7.126000E-02 |
| Caucasian-vs-Asian |
4.137800E-01 |
| AfricanAmerican-vs-Asian |
6.735500E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
8.77076189453874E-15 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
9.427600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.86606285978996E-12 |
| Normal-vs-Age(41-60Yrs) |
1.4432899320127E-15 |
| Normal-vs-Age(61-80Yrs) |
3.37074812506444E-12 |
| Normal-vs-Age(81-100Yrs) |
1.784170E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.332800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.819800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.766000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.390200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.874600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.968800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.627200E-04 |
| Classical-VS-Follicular |
8.356100E-03 |
| Classical-VS-Other |
9.724600E-01 |
| Classical-VS-Normal |
1.35969013825843E-12 |
| Tall-VS-Follicular |
2.1390000000121E-06 |
| Tall-VS-Other |
3.753800E-01 |
| Tall-VS-Normal |
8.88178419700125E-16 |
| Follicular-VS-Other |
4.255800E-01 |
| Follicular-VS-Normal |
6.95630000269176E-08 |
| Other-VS-Normal |
2.161400E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.15223411209809E-14 |
| Normal-vs-N1 |
5.78348480217983E-12 |
| N0-vs-N1 |
1.961810E-01 |
|
|
